drugset / Trial / NCT01900054

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01900054

Phase 3 Completed 58 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

Timeline

Start
2013-06
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepotastine Small molecule 10 mg Oral